ML329 Biomarker Profiling for CK2-Targeted Cancer Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanism of action of ML329, a small molecule inhibitor of microphthalmia-associated transcription factor (MITF), is unknown, hindering the development of effective diagnostic, prognostic, and therapeutic strategies for cancer treatment.
Innovation Solution
ML329 is selectively converted into an active form by NAD(P)H quinone dehydrogenase 1 (NQO1) in cancer cells, inhibiting casein kinase II (CK2) through an ATP-competitive mechanism, with biomarkers such as NQO1, NRF2, and KEAP1 mutations predicting responsiveness to ML329 treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ML329 is used as an inhibitor of microphthalmia-associated transcription factor (MITF), then cancer cell proliferation is reduced, but the mechanism of action is unknown and biomarkers for selecting responsive subjects are unavailable
Solution Approach 1:
The patent performs preliminary investigative actions by conducting comprehensive mechanistic studies, cell line screenings, and biomarker analyses before clinical application. Research teams systematically explored ML329's mechanism through multiple preliminary experiments, identifying NQO1 as the activating enzyme and CK2 as the target, thereby resolving the information gap before therapeutic deployment
Solution Approach 2:
The patent establishes feedback loops by measuring biomarker levels (NQO1, NRF2, KEAP1) in patient samples and using this information to predict treatment response. This feedback mechanism allows clinicians to select patients most likely to benefit from ML329 therapy, transforming the previously unknown mechanism into a actionable diagnostic tool
2Object-affected harmful factors
If ML329 is converted into an active form by NQO1 in cancer cells, then selective targeting of cancer cells is achieved, but the requirement for metabolic activation limits applicability to cancers with high NQO1 expression
Solution Approach 1:
The patent exploits local quality differences by targeting the specific metabolic characteristic of high NQO1 expression in certain cancer cells. The prodrug ML329 is designed to be activated only in cells with elevated NQO1 activity, creating a localized therapeutic effect that spares normal cells and cancers with low NQO1 expression. This selective activation based on local metabolic quality achieves both cancer cell selectivity and defined applicability
Solution Approach 2:
The patent changes the chemical parameter of ML329 from inactive prodrug form to active form through NQO1-mediated metabolic conversion. This parameter change (chemical transformation) is controlled by the presence and activity of NQO1 enzyme, thereby enabling selective activation only in cancer cells with high NQO1 expression levels, resolving the contradiction between selectivity and versatility
3Measurement precision
If biomarkers such as NQO1, NRF2, and KEAP1 mutations are measured to predict responsiveness to ML329, then treatment efficacy can be predicted, but diagnostic and prognostic assays require additional time and resources
Solution Approach 1:
The patent performs preliminary biomarker assessments using readily available clinical samples (tumor tissue, blood) and established molecular techniques (PCR, sequencing, IHC) before treatment decisions are made. By conducting these measurements in advance and establishing predictive algorithms, the system minimizes delays during actual treatment planning
Solution Approach 2:
The patent introduces biomarker analysis as an intermediary step between cancer diagnosis and treatment selection. This intermediary layer provides precise prediction of treatment response, allowing clinicians to make informed decisions about ML329 therapy. The intermediary biomarker assessment bridges the gap between general cancer diagnosis and specific treatment efficacy, justifying the additional time and resources through improved treatment outcomes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Biomarkers identify cancer cells likely to respond to ML329, enabling targeted therapeutic strategies and predicting treatment efficacy, including combinations with other therapies like immunotherapy.
Implementation Method 1
ML329 and derivatives thereof are bioreduced by an enzyme, NAD(P)H quinone dehydrogenase 1 (NQO1), which is preferentially expressed in some cancer types. The bioreduction is required to convert ML329 and derivatives thereof into an active form.
Implementation Method 2
ML329 binds to CK2alpha and CK2alpha prime (two subunits of the CK2 holoenzyme) in vitro and inhibits CK2 activity in an ATP-competitive manner.
Data Source
AI summary
The present invention is based in part on the identification of biomarkers, including NQO1, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.